NASDAQ:ALNA - Allena Pharmaceuticals Stock Price, Forecast & News

Allena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNA."

Allena Pharmaceuticals Inc (NASDAQ:ALNA) issued its earnings results on Wednesday, November, 13th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.49) by $0.08. View Allena Pharmaceuticals' Earnings History.

Allena Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Allena Pharmaceuticals.

4 equities research analysts have issued 12-month price objectives for Allena Pharmaceuticals' shares. Their forecasts range from $4.00 to $31.00. On average, they expect Allena Pharmaceuticals' share price to reach $20.75 in the next twelve months. This suggests a possible upside of 693.5% from the stock's current price. View Analyst Price Targets for Allena Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allena Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Allena Pharmaceuticals.

Headlines about ALNA stock have been trending neutral on Tuesday, according to InfoTrie Sentiment. The research group rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Allena Pharmaceuticals earned a news sentiment score of 0.5 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for Allena Pharmaceuticals.

Allena Pharmaceuticals saw a drop in short interest in December. As of December 31st, there was short interest totalling 616,200 shares, a drop of 7.2% from the December 15th total of 664,300 shares. Based on an average daily trading volume, of 471,900 shares, the short-interest ratio is currently 1.3 days. Currently, 5.4% of the company's shares are sold short. View Allena Pharmaceuticals' Current Options Chain.

Some companies that are related to Allena Pharmaceuticals include Jounce Therapeutics (JNCE), La Jolla Pharmaceutical (LJPC), Novavax (NVAX), Solid Biosciences (SLDB), LogicBio Therapeutics (LOGC), Windtree Therapeutics (WINT), Dyadic International (DYAI), Applied Genetic Technologies (AGTC), Erytech Pharma (ERYP), X4 Pharmaceuticals (XFOR), Cidara Therapeutics (CDTX), Fennec Pharmaceuticals (FENC), Axcella Health (AXLA), Gamida Cell (GMDA) and Polarityte (PTE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Allena Pharmaceuticals investors own include Viking Therapeutics (VKTX), Pieris Pharmaceuticals (PIRS), Exelixis (EXEL), Fate Therapeutics (FATE), Sorrento Therapeutics (SRNE), Obseva (OBSV), Stemline Therapeutics (STML), Arrowhead Pharmaceuticals (ARWR), Clearside Biomedical (CLSD) and Catalyst Pharmaceuticals (CPRX).

(ALNA) raised $80 million in an IPO on Thursday, November 2nd 2017. The company issued 5,300,000 shares at $14.00-$16.00 per share. Credit Suisse, Jefferies and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Allena Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Wedbush Securities Inc. (0.21%). View Institutional Ownership Trends for Allena Pharmaceuticals.

ALNA stock was acquired by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. View Insider Buying and Selling for Allena Pharmaceuticals.

Shares of ALNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ALNA stock can currently be purchased for approximately $2.62.

Allena Pharmaceuticals has a market capitalization of $61.37 million. The company earns $-35,650,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis. Allena Pharmaceuticals employs 49 workers across the globe.View Additional Information About Allena Pharmaceuticals.

The official website for Allena Pharmaceuticals is http://www.allenapharma.com/.

Allena Pharmaceuticals' mailing address is ONE NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA, 02462. The company can be reached via phone at 617-467-4577.